AVXS

Avexis Inc

A biotech company that makes Zolgensma, a one-time gene therapy for spinal muscular atrophy (SMA), a rare genetic disease that weakens muscles in young children. Founded in Dallas in 2012 when John Carbona reorganized a stem-cell bank called BioLife Cell Bank, AveXis built its treatment on research from Nationwide Children's Hospital. It was acquired by pharma giant Novartis in 2018.

No Schedule 13D or 13G filings recorded.